Stocks in Action USA: Regeneron Pharmaceuticals, Ulta Beauty, Zscaler
Reading Time: 3 minutes
Regeneron (REGN) stock plummets – drug candidate against COPD disappointed in a late phase! The stock of Regeneron Pharmaceuticals came under significant pressure on May 30 after the biotech company released disappointing results from two critical studies on a COPD medication developed in collaboration with Sanofi . The drug Itepekimab, an IL-33 antibody, was expected to bring hope in the fight against chronic obstructive pulmonary disease (COPD) – a leading cause of death worldwide with over 3.5 million fatalities in 2021 according to WHO....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
